Salivary gland cancer

Researchers are testing whether combining cetuximab, a drug that blocks tumor growth, with stereotactic body radiation therapy can help patients whose head and neck cancer has returned after earlier radiation and cannot be removed by surgery. The trial enrolls about 45 people wit…

This study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…

This phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to se…

This phase II trial tested whether adding sorafenib to cetuximab works better than cetuximab alone for patients with advanced head and neck cancer that has come back or spread. Fifty-five adults with various types of head and neck cancer took part. The study measured how long pat…

This study tested whether analyzing the genes of a person's salivary gland tumor could help doctors pick a more effective drug. 114 people with advanced or returning cancer joined. First, their tumor was genetically profiled. Then, if a targetable gene change was found, they got …

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 64 people with recurrent or metastatic salivary gland cancer that could not be removed by surgery or treated with radiation. The goal was to see how well the combination shrank tumors and what side effects oc…

This pilot study tested whether applying prescription fluoride varnish to teeth every three months during the first year after radiation therapy for head and neck cancer can reduce cavities and gum problems. 13 adults with at least 4 natural teeth and certain cancers took part. T…

This early-phase trial tested two doses of the drug erlotinib (Tarceva) given before surgery in 48 people with head and neck cancer. The goal was to see how the drug affects a protein called phospho-Akt in tumor samples. Researchers hope erlotinib might slow tumor growth by block…

Researchers are studying whether PET scans help doctors plan radiation more precisely for people with locally advanced head and neck cancer. Participants receive 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, which shape beams to the tumor. T…

This study looked at whether acupuncture can reduce dry mouth (xerostomia) caused by radiation therapy in people with head and neck cancer. A total of 258 participants were randomly assigned to receive acupuncture or usual care. The main goal was to see if acupuncture improved dr…

This study follows head and neck cancer patients who received radiation therapy to see how many teeth they lose over two years. It also looks at other mouth problems like dry mouth and bone damage. The goal is to better understand and manage these long-term side effects.

This completed trial tested a mobile app and web platform (BD4QoL) to monitor quality of life in 410 head and neck cancer survivors after curative treatment. The goal was to see if the platform could reduce or catch early declines in quality of life compared to standard follow-up…